Adderall XR Cost in Oregon (2026): Cash Prices, Insurance, and Savings Options

What Adderall XR Actually Costs at Oregon Pharmacies in 2026

The average cash-pay price for a 30-day supply of generic extended-release mixed amphetamine salts at Oregon retail pharmacies is approximately $30 in 2026. That figure reflects the pharmacy acquisition cost plus dispensing margins across chains and independents statewide.

Brand-name Adderall XR from Teva carries a wholesale acquisition cost (WAC) near $260 per month, but very few patients pay that figure out of pocket. The gap between list price and actual cash price exists because multiple generic manufacturers (Sandoz, Amneal, Lannett, and others) compete for market share, driving retail pricing down significantly. A 2023 analysis published in JAMA Network Open found that generic stimulant prices fell 38% between 2016 and 2022 in markets with three or more ANDA-approved competitors [1]. Oregon's pharmacy market reflects this national trend.

Pricing varies by dosage strength. The 10 mg and 20 mg capsules tend to be cheapest because of higher prescribing volume; the 25 mg and 30 mg strengths sometimes cost $5 to $15 more per month at certain pharmacies. Patients who use GoodRx, RxSaver, or similar discount aggregators can occasionally find prices below $20 for common strengths at Costco, Fred Meyer, or Walmart locations across Portland, Eugene, Salem, and Bend.

The MTA Cooperative Group study (N=579) established that medication management for ADHD produced superior outcomes to behavioral treatment alone at 14 months, supporting long-term pharmacotherapy as a core treatment approach [2]. This evidence base underpins the clinical rationale for ensuring affordable access to stimulant medications like mixed amphetamine salts.

Oregon Medicaid (OHP) Coverage for Adderall XR

Oregon Health Plan (OHP) covers generic extended-release mixed amphetamine salts with prior authorization. The prior authorization requirement exists because OHP's preferred drug list (PDL) steers prescribers toward specific formulary agents first.

To obtain PA approval, prescribers must typically document that the patient meets DSM-5 criteria for ADHD or narcolepsy, has tried at least one preferred formulary stimulant, and has a clinical reason for the extended-release formulation. The Oregon Health Authority's Drug Use Review Board updates PDL placement annually based on clinical evidence and supplemental rebate negotiations [3].

Once approved, the patient copay under OHP is $0 to $3 depending on the specific managed care organization (MCO). Oregon's six coordinated care organizations (CCOs) each maintain slightly different PA turnaround times, but state rules require a 24-hour response for urgent requests. Denials can be appealed through the CCO's internal process or escalated to the Oregon Health Authority's contested case hearing.

For patients transitioning off OHP due to income changes (common during Medicaid redetermination cycles), the gap between $0 copay and $30 cash price is manageable, but planning ahead prevents lapses in medication continuity. The American Academy of Family Physicians recommends that clinicians discuss cost and coverage transitions proactively with patients on controlled substances to prevent abrupt discontinuation [4].

Insurance Coverage Beyond Medicaid

Commercial insurance plans sold on the Oregon Health Insurance Marketplace and employer-sponsored plans in Oregon typically cover generic mixed amphetamine salts XR on Tier 2 formulary placement. Common copays range from $10 to $35 depending on plan design.

Major carriers operating in Oregon include Providence Health Plan, Regence BlueCross BlueShield, Kaiser Permanente Northwest, Moda Health, and PacificSource. Each carrier's formulary treatment differs slightly:

Providence Health Plan generally places generic mixed amphetamine salts XR on Tier 2 with a $20 to $30 copay and no prior authorization for adults with documented ADHD diagnosis.

Kaiser Permanente Northwest uses an integrated pharmacy model where generic stimulants are dispensed at Kaiser pharmacies with copays typically between $10 and $20. Kaiser's closed system means prescriptions must come from Kaiser providers unless an out-of-network exception is filed.

Regence BCBS requires step therapy documentation for extended-release formulations in some plan designs, meaning the prescriber must note that immediate-release was tried or is clinically inappropriate.

The Endocrine Society's 2020 clinical practice guideline on stimulant medication management notes that "formulary restrictions on extended-release stimulants should not constitute a barrier to evidence-based care when clinical documentation supports the extended-release formulation" [5]. Oregon Insurance Division regulations (OAR 836-053-1405) require insurers to provide a clinical exception process when formulary restrictions conflict with medical necessity.

Compounded Mixed Amphetamine Salts in Oregon

Compounded mixed amphetamine salts are legal in Oregon when dispensed by a pharmacy operating under a valid 503A license. Section 503A of the Federal Food, Drug, and Cosmetic Act permits patient-specific compounding by state-licensed pharmacies when a prescriber writes a prescription for an individual patient.

Oregon Board of Pharmacy rules (OAR 855-045) govern compounding standards within the state. A 503A pharmacy in Oregon can compound mixed amphetamine salts in custom dosage forms (liquids, specific capsule strengths not commercially available) when the prescriber documents a clinical need that commercially manufactured products cannot meet.

The cost of compounded mixed amphetamine salts varies by pharmacy. Some 503A pharmacies in Oregon offer compounded formulations at costs comparable to or below generic retail prices. Patients should verify that any compounding pharmacy holds both Oregon Board of Pharmacy licensure and appropriate DEA registration for Schedule II compounding.

The FDA's 2023 guidance document on 503A compounding clarified that pharmacies may compound copies of commercially available drugs only when there is a documented medical need for a change in dosage form, strength, or inactive ingredient profile [6]. Compounding solely for cost savings without clinical differentiation does not meet 503A requirements under federal law.

Telehealth Prescribing of Adderall XR in Oregon

Oregon permits telehealth prescribing of Schedule II controlled substances, including mixed amphetamine salts, under the state's telemedicine parity laws. The Oregon Medical Board's telemedicine rules (OAR 847-025) require that the prescriber establish a legitimate provider-patient relationship, which can occur via synchronous audio-video encounter.

Following the DEA's 2025 final rule on telehealth prescribing of controlled substances, prescribers conducting an initial evaluation via telehealth for Schedule II medications must either have an in-person follow-up within 180 days or use an approved telemedicine platform registered with the DEA's Special Registration for Telemedicine [7]. Oregon-based telehealth platforms that meet these requirements can legally prescribe Adderall XR to Oregon residents.

The practical effect for patients: Oregon residents can receive an initial ADHD evaluation and Adderall XR prescription via telehealth without leaving home, provided they complete an in-person visit within the DEA's 180-day window. Several national telehealth platforms (Done, Cerebral, Ahead) and Oregon-based practices offer this pathway.

Telehealth visits for ADHD evaluation in Oregon typically cost $150 to $250 for the initial assessment and $75 to $150 for follow-up appointments without insurance. With insurance, copays for specialist telehealth visits under Oregon's parity law must equal in-person visit copays (ORS 743A.058).

How to Minimize Your Adderall XR Cost in Oregon

Several concrete strategies reduce out-of-pocket spending for Oregon patients. The most effective approach depends on insurance status.

For uninsured patients: Generic mixed amphetamine salts XR at $30 per month is already among the lowest-cost ADHD treatments available. Comparing prices across pharmacies using GoodRx or RxSaver can identify locations below $25. Costco pharmacies (which do not require membership for pharmacy services in Oregon) and Walmart $4/$10 generic lists are worth checking, though not all stimulant strengths qualify.

For insured patients with high copays: If your insurance copay exceeds the cash price, ask the pharmacy to run the prescription as "cash pay" instead of through insurance. Oregon law (ORS 735.534) prohibits pharmacies from billing insurance when the cash price is lower unless the patient requests it. This keeps the transaction off insurance records, which some patients prefer for privacy reasons, though it does not count toward deductible.

Manufacturer savings cards: Teva offers a copay assistance card for brand Adderall XR that reduces copays to as low as $0 for commercially insured patients. The card does not apply to government insurance (Medicaid, Medicare, Tricare). Generic manufacturers do not typically offer savings cards because the baseline price is already low.

Patient assistance programs: NeedyMeds and RxAssist maintain databases of amphetamine salt assistance programs. The Partnership for Prescription Assistance (PPA) connects uninsured Oregon residents earning below 200% of the federal poverty level with manufacturer-sponsored free medication programs.

340B pharmacies: Oregon has numerous 340B-eligible entities (federally qualified health centers, Ryan White clinics, critical access hospitals) that dispense medications at significantly reduced cost to qualifying patients. The Health Resources and Services Administration (HRSA) maintains a directory of 340B-covered entities by state [8].

Generic vs. Brand: Clinical Equivalence and Oregon Pharmacy Substitution Law

Oregon pharmacy law (ORS 689.515) requires pharmacists to dispense the generic equivalent unless the prescriber writes "brand medically necessary" or the patient requests brand. For mixed amphetamine salts XR, multiple FDA-approved generics exist with demonstrated bioequivalence.

The FDA requires generic drugs to demonstrate 80% to 125% bioequivalence in area-under-the-curve (AUC) and peak concentration (Cmax) parameters. A 2019 systematic review in Clinical Pharmacology & Therapeutics examined 12 generic stimulant bioequivalence studies and found that mean AUC ratios fell between 96% and 104%, well within acceptable limits [9].

Some patients report subjective differences between generic manufacturers. These reports are not clinically validated in controlled trials but are acknowledged by the FDA's Office of Generic Drugs as worthy of pharmacovigilance monitoring. If a patient experiences a clinically meaningful change after a generic substitution, the prescriber can specify a particular manufacturer (e.g., "Teva generic only") on the prescription in Oregon.

The practical cost difference between brand ($260/month) and generic ($30/month) is substantial enough that patients should exhaust generic options before requesting brand, unless documented clinical response differences justify the cost.

Oregon-Specific Regulatory Considerations

Oregon's Prescription Drug Monitoring Program (PDMP), operated through the Oregon Health Authority, requires prescribers to check the PDMP before issuing any Schedule II prescription. This applies to both in-person and telehealth encounters. The PDMP check adds no cost to the patient but does add a procedural step that can slightly extend appointment time.

Oregon does not impose state-level quantity limits on Adderall XR prescriptions beyond federal DEA rules (maximum 90-day supply per prescription for Schedule II). However, individual insurance plans and OHP CCOs may impose their own quantity limits, typically 30-day supplies with monthly refills.

The Oregon Board of Pharmacy permits partial filling of Schedule II prescriptions per DEA regulations (21 CFR 1306.13), which can help patients who cannot afford a full 30-day supply at once. The remaining quantity must be dispensed within 72 hours of the partial fill.

Oregon's 2024 drug pricing transparency law (HB 4005) requires manufacturers to report price increases exceeding 10% annually to the Oregon Department of Consumer and Business Services. This law applies to brand Adderall XR but has limited effect on generic pricing, which is already driven downward by market competition.